Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
Dignass, Axel U
Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis. [electronic resource] - Scandinavian journal of gastroenterology Feb 2019 - 178-187 p. digital
Publication Type: Comparative Study; Journal Article; Meta-Analysis; Systematic Review
1502-7708
10.1080/00365521.2019.1569124 doi
Adalimumab--therapeutic use
Anti-Inflammatory Agents--therapeutic use
Antibodies, Monoclonal, Humanized--therapeutic use
Biological Products--therapeutic use
Colitis, Ulcerative--drug therapy
Gastrointestinal Agents--therapeutic use
Humans
Quality of Life
Randomized Controlled Trials as Topic
Treatment Outcome
Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis. [electronic resource] - Scandinavian journal of gastroenterology Feb 2019 - 178-187 p. digital
Publication Type: Comparative Study; Journal Article; Meta-Analysis; Systematic Review
1502-7708
10.1080/00365521.2019.1569124 doi
Adalimumab--therapeutic use
Anti-Inflammatory Agents--therapeutic use
Antibodies, Monoclonal, Humanized--therapeutic use
Biological Products--therapeutic use
Colitis, Ulcerative--drug therapy
Gastrointestinal Agents--therapeutic use
Humans
Quality of Life
Randomized Controlled Trials as Topic
Treatment Outcome